Back to Search
CORISSA SCHNELL, PHARMD
PHARMD
Pharmacist
NPI: 1336125541Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
117526-4(MN)
Research & Publications (20)
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
PMID 19223496·Clin Cancer Res·2009
4-observational
Astrocytic calcium signals induced by neuromodulators via functional metabotropic receptors in the ventral respiratory group of neonatal mice.
PMID 19031447·Glia·2009
7-preclinical
PI3K inhibitors for cancer treatment: where do we stand?
PMID 19143644·Biochem Soc Trans·2009
6-review
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
PMID 19372588·Mol Cancer Res·2009
7-preclinical
Glycinergic interneurons are functionally integrated into the inspiratory network of mouse medullary slices.
PMID 19238427·Pflugers Arch·2009
7-preclinical
The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.
PMID 19615901·Bioorg Med Chem Lett·2009
7-preclinical
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
PMID 18316624·Cancer Res·2008
7-preclinical
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
PMID 18701483·Cancer Res·2008
7-preclinical
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
PMID 18606717·Mol Cancer Ther·2008
7-preclinical
The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis.
PMID 18155761·Biomaterials·2008
7-preclinical
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
PMID 17824680·J Med Chem·2007
7-preclinical
Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin.
PMID 17824679·J Med Chem·2007
7-preclinical
Minimally invasive biomarkers for therapy monitoring.
PMID 18811057·Ernst Schering Found Symp Proc·2007
7-preclinical
Behavioral and physiological effects of an infant-neglect manipulation in a bi-parental, twinning primate: impact is dependent on familial factors.
PMID 17363175·Psychoneuroendocrinology·2007
7-preclinical
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
PMID 16397235·Cancer Res·2006
7-preclinical
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
PMID 16172907·Cancer Chemother Pharmacol·2006
3-trial
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
PMID 15918178·NMR Biomed·2005
7-preclinical
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
PMID 15958638·Clin Cancer Res·2005
7-preclinical
Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
PMID 16278399·Clin Cancer Res·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1336125541
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile